Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RIGL 
Rigel Pharmaceuticals Inc (RIGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: RIGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -16.75% | Avg. Invested days 27 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 306.35M USD | Price to earnings Ratio 17.32 | 1Y Target Price 33.67 |
Price to earnings Ratio 17.32 | 1Y Target Price 33.67 | ||
Volume (30-day avg) 233300 | Beta 1.35 | 52 Weeks Range 7.48 - 29.82 | Updated Date 04/1/2025 |
52 Weeks Range 7.48 - 29.82 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-04 | When After Market | Estimate 0.5789 | Actual 0.8 |
Profitability
Profit Margin 9.75% | Operating Margin (TTM) 28.92% |
Management Effectiveness
Return on Assets (TTM) 10.75% | Return on Equity (TTM) -699.05% |
Valuation
Trailing PE 17.32 | Forward PE 20.33 | Enterprise Value 328974720 | Price to Sales(TTM) 1.79 |
Enterprise Value 328974720 | Price to Sales(TTM) 1.79 | ||
Enterprise Value to Revenue 1.68 | Enterprise Value to EBITDA 10.59 | Shares Outstanding 17863000 | Shares Floating 15340172 |
Shares Outstanding 17863000 | Shares Floating 15340172 | ||
Percent Insiders 2.84 | Percent Institutions 68.82 |
Analyst Ratings
Rating 3.5 | Target Price 31.33 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rigel Pharmaceuticals Inc
Company Overview
History and Background
Rigel Pharmaceuticals Inc. was founded in 1996. It is a biotechnology company focused on discovering and developing novel, small-molecule drugs for hematologic disorders, cancer, and immune diseases.
Core Business Areas
- Hematology/Oncology: Development and commercialization of therapies for blood disorders and cancers, primarily focusing on TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP).
- Immunology: Researching and developing treatments for immune diseases.
Leadership and Structure
The leadership team includes prominent figures in the pharmaceutical industry, overseeing research and development, commercialization, and corporate strategy. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- TAVALISSE (fostamatinib): TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Competing products include Amgen's Nplate and Novartis' Promacta, which are thrombopoietin receptor agonists.
- Rezlidhia (olutasidenib): Rezlidhia is an oral inhibitor of isocitrate dehydrogenase-1 (IDH1) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test. Competitors include Tibsovo (ivosidenib) from Servier Pharmaceuticals.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and competition for innovative therapies. The ITP and AML markets are growing due to aging populations and increased diagnosis rates.
Positioning
Rigel is a specialty pharmaceutical company focused on hematology and oncology. It is positioned as an innovator in targeted therapies, particularly with its SYK inhibitor TAVALISSE. Rigel is also positioned to capture a percentage of the IDH1 market with Rezlidhia (olutasidenib).
Total Addressable Market (TAM)
The TAM for ITP is estimated to be in the billions of dollars. The TAM for IDH1-mutated AML is also significant. Rigel's position with TAVALISSE and Rezlidhia provides it with access to a portion of these large markets.
Upturn SWOT Analysis
Strengths
- Approved product (TAVALISSE) generating revenue
- Strong focus on hematology and oncology
- Innovative SYK inhibitor platform
- Partnerships for global commercialization
- Rezlidhia approval
Weaknesses
- Dependence on a limited number of products
- High research and development expenses
- Competition from established pharmaceutical companies
- Need for additional capital to fund operations
Opportunities
- Expansion of TAVALISSE into new indications
- Development of new therapies for hematologic disorders
- Strategic partnerships and acquisitions
- Potential for global expansion
- Further studies in unmet medical needs in AML
Threats
- Regulatory hurdles and delays
- Competition from biosimilars and generics
- Clinical trial failures
- Economic downturn impacting healthcare spending
- Patent expirations
Competitors and Market Share
Key Competitors
- NVS
- AMGN
- TAK
Competitive Landscape
Rigel faces competition from larger pharmaceutical companies with established brands and greater resources. Rigel's competitive advantage lies in its innovative SYK inhibitor platform and focus on targeted therapies.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the commercialization of TAVALISSE, with fluctuations based on sales performance and clinical trial results.
Future Projections: Future growth depends on the success of TAVALISSE in existing and new indications, the development of new products, and strategic partnerships. Analyst estimates are needed to make projections.
Recent Initiatives: Recent initiatives include expanding the TAVALISSE label, advancing pipeline programs, and pursuing strategic collaborations. The Rezlidhia approval and expansion of the commercial team are other recent initiatives.
Summary
Rigel Pharmaceuticals is a specialty pharmaceutical company with an approved product generating revenue and a focused pipeline. Its innovative technology and strategic partnerships are working well, but the company needs to manage its limited product portfolio and face competition from bigger players. Successful pipeline development and market expansion are crucial for sustained growth. Management needs to carefully manage cash and future R&D to increase shareholders value.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Analyst Reports
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data are approximations and may vary. Financial data are based on publicly available information, and accuracy is not guaranteed. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rigel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2000-11-29 | President, CEO & Director Mr. Raul R. Rodriguez | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://www.rigel.com |
Full time employees 162 | Website https://www.rigel.com | ||
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.